Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Lyell Immunopharma

Request full access

Operator of a biotechnology company that develops cellular therapies to cure cancer

San Francisco, United StatesFounded 2018Biotech & Life Sciences

At a glance

Status
Listed
Listing
IPO 2021

Lyell Immunopharma in the San Francisco ecosystem

Live from Dealroom

The Lyell Immunopharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

Series B and later1 investor entered at this stage

  • University of Washington
Employees mapped 233 incl. 1 AI specialist
Founders Hidden — book a demo/100 quality score
Key operators 16 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$8M

35 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Investments and acquisitions

Disclosed deals where Lyell Immunopharma was the backer or acquirer, 2020–2024. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

6 deals across Lyell Immunopharma's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        Where Lyell Immunopharma deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        Lyell Immunopharma's portfolio, mapped.

        Stage
        Period
        6 of 6 deals

        See Lyell Immunopharma on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.